Gemini Therapeutics Provides GEM103 Program Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program. GEM103 Phase 2a ReGAtta Study Update Ongoing analysis of the 62 patients enrolled in the ReGAtta study continues to show that more than n